1-3 of 3
Caitlin E. Schutz
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Asciminib is a novel inhibitor of ABL1 and ABL2 gene fusions in ALL but requires the ABL SH3 domain for efficacy

Laura N. Eadie, Elias Lagonik, Elyse C. Page, Caitlin E. Schutz, Susan L. Heatley, Barbara J. McClure, Michelle O. Forgione, David T. Yeung, Timothy P. Hughes, Deborah L. White
Journal: Blood
Blood (2024) 144 (9): 1022–1026.
https://doi.org/10.1182/blood.2024024776
Published: 2024
Includes: Supplemental data
Journal Articles

Improved MRD Negativity Rates in Adverse Genomic Risk B-ALL Patients with Chemotherapy / Blinatumomab Induction: Experience from the Australasian Leukaemia Lymphoma Group (ALLG) ALL06/09 Studies

Deborah L White, Jacqueline A Rehn, Caitlin E Schutz, Susan L Heatley, Laura N Eadie, Ashlee Thomson, Elyse C Page, Michael Osborn, Shane Gangatharan, Ashley P Ng, Shaun Fleming, Pasquale Fedele, Toby Trahair, John Casey, Sally Mapp, Carol CY Cheung, Tasman Armytage, Michelle Henderson, Rosemary Sutton, Stephen Robert Larsen, Peter Presgrave, John Kwan, Samuel Bennett, Chun Yew Fong, Luciano Dalla-Pozza, David T Yeung, Matthew Greenwood
Journal: Blood
Blood (2023) 142 (Supplement 1): 1609.
https://doi.org/10.1182/blood-2023-178473
Published: 2023
Journal Articles

Asciminib Is Effective Against ABL1 Gene Fusions in Acute Lymphoblastic Leukemia but Only When the ABL1 SH3 Domain Is Present

Laura N Eadie, Caitlin E Schutz, Elyse C Page, Tace S Conlin, Susan L Heatley, Elias Lagonik, Jacqueline A Rehn, David T Yeung, Timothy P Hughes, Deborah L White
Journal: Blood
Blood (2023) 142 (Supplement 1): 1602.
https://doi.org/10.1182/blood-2023-184647
Published: 2023